Skip to main content
Equibles

TD Asset Management Inc

Position in RNA — Atrium Therapeutics, Inc.

CIK 1056053 Toronto, A6
Back to RNA Full portfolio

Position in RNA

as of Jun 30, 2026 · filed Aug 4, 2026
Position Value
$1,495,640
+$8,896 QoQ
Shares Held
111,200
0.0% QoQ
Ownership
0.650%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#35
of 154 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in RNA Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

TD Asset Management Inc holds $1,140,636,067 across 120 Biotechnology names. RNA ranks #84 (0.1% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 REGN
Regeneron Pharmaceuticals, Inc.
 259,317 $161,694,522
2 VRTX
Vertex Pharmaceuticals Inc / Ma
 207,960 $103,299,970
3 HALO
Halozyme Therapeutics, Inc.
 1,115,730 $87,328,187
4 ALNY
Alnylam Pharmaceuticals, Inc.
 233,696 $70,349,506
5 CYTK
Cytokinetics Inc
 385,130 $32,809,224
6 RPRX
Royalty Pharma plc
 567,497 $31,819,556
7 ASND
Ascendis Pharma A/S
 119,085 $31,762,351
8 KYMR
Kymera Therapeutics, Inc.
 272,900 $31,293,443

All Filings in RNA

Export CSV
2 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $1,495,640 111,200
2026-03-31 $1,486,744 111,200